Endologix to Present at Three Upcoming Investor Conferences

IRVINE, Calif., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences and Bob Krist, Chief Financial Officer, is scheduled to present at one upcoming conference. The first presentation will be at the 23rd Annual Piper Jaffray Health Care Conference in New York City.

**Event:** 23rd Annual Piper Jaffray Health Care Conference  
**Date:** Wednesday, November 30, 2011  
**Time:** 9:30 a.m. ET / 6:30 a.m. PT  
**Endologix Participant:** John McDermott, President and Chief Executive Officer

The second presentation will be at the 6th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference in San Francisco.

**Event:** 6th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference  
**Date:** Tuesday, December 6, 2011  
**Time:** 5:00 p.m. ET / 2:00 p.m. PT  
**Endologix Participant:** Bob Krist, Chief Financial Officer

The Third presentation will be at the Oppenheimer 22nd Annual Healthcare Conference in New York City.

**Event:** Oppenheimer 22nd Annual Healthcare Conference  
**Date:** Tuesday, December 13, 2011  
**Time:** 9:40 a.m. ET / 6:40 a.m. PT  
**Endologix Participant:** John McDermott, President and Chief Executive Officer

An audio webcast of the Company's presentations will be available by visiting the investor relations section of Endologix's website at [www.endologix.com](http://www.endologix.com). A replay of the presentations will be available for 30 days.

**About Endologix, Inc.**

Endologix, Inc. (the "Company") develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at [www.endologix.com](http://www.endologix.com).

**CONTACT: COMPANY CONTACT:**

Endologix, Inc.

John McDermott, CEO
INVESTOR CONTACTS:

The Ruth Group

Nick Laudico (646) 536-7030

Zack Kubow (646) 536-7020

Source: Endologix

News Provided by Acquire Media